Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Written informed consent, age-adapted~* Male or female aged 1 to 70 years~* Diagnosis of primary humoral immunodeficiency~* No prior immunoglobulin substitution therapy~* IgG level of \<5 g/L at screening~* Women of childbearing potential must use medically approved contraception and must have a negative urine pregnancy test at screening~Key Exclusion Criteria:~* Evidence of serious infection between screening and first treatment~* Bleeding disorders that require medical treatments~* Any medical disorder causing secondary immune disorders, autoimmune neutropenia, or a clinically significant defect in cell mediated immunity~* Any condition likely to interfere with evaluation of the study drug or satisfactory conduct of the trial

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Vivaglobin (Type: EXPERIMENTAL): Vivaglobin: 16% (160 mg/mL) liquid formulation of human IgG for SC use. Loading dose: 100 mg/kg for 5 consecutive days; maintenance dose: 100 mg/kg 1 to 2 times a week for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).